GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Price-to-Owner-Earnings

Prostatype Genomics AB (OSTO:PROGEN) Price-to-Owner-Earnings : (As of Jun. 02, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Price-to-Owner-Earnings?

As of today (2024-06-02), Prostatype Genomics AB's share price is kr0.062. Prostatype Genomics AB does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Prostatype Genomics AB's Price-to-Owner-Earnings or its related term are showing as below:


OSTO:PROGEN's Price-to-Owner-Earnings is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 25.36
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-02), Prostatype Genomics AB's share price is kr0.062. Prostatype Genomics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was kr-0.28. Therefore, Prostatype Genomics AB's PE Ratio for today is At Loss.

As of today (2024-06-02), Prostatype Genomics AB's share price is kr0.062. Prostatype Genomics AB's EPS without NRI for the trailing twelve months (TTM) ended in was kr-0.28. Therefore, Prostatype Genomics AB's PE Ratio without NRI for today is At Loss.


Prostatype Genomics AB Price-to-Owner-Earnings Historical Data

The historical data trend for Prostatype Genomics AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Price-to-Owner-Earnings Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

Prostatype Genomics AB Quarterly Data
Jun18 Jun19 Mar20 Jun20 Sep20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Prostatype Genomics AB's Price-to-Owner-Earnings

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prostatype Genomics AB's Price-to-Owner-Earnings Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Price-to-Owner-Earnings falls into.



Prostatype Genomics AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Prostatype Genomics AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.062/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prostatype Genomics AB  (OSTO:PROGEN) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Prostatype Genomics AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Prostatype Genomics AB (OSTO:PROGEN) Business Description

Traded in Other Exchanges
Address
Gustaf III:s Boulevard 34, Solna, SWE, 169 73
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines